Revolution Medicines, Inc.
SHP2 INHIBITOR COMPOSITIONS FOR USE IN TREATING CANCER
Last updated:
Abstract:
The present disclosure provides methods of treating diseases or disorders using allosteric inhibitors of SHP2 and to methods and diagnostic tests for identifying subjects likely to respond to such allosteric inhibitors of SHP2. In particular, the present disclosure provides diagnostic and therapeutic uses related to certain Receptor Tyrosine Kinase (RTK) mutations that are indicative of sensitivity to allosteric SHP2 inhibitors.
Status:
Application
Type:
Utility
Filling date:
6 Apr 2021
Issue date:
3 Feb 2022